ENZ vs. QIPT, CORBF, EUDA, PIII, BNR, XGN, TOI, CCM, PMD, and MRAI
Should you be buying Enzo Biochem stock or one of its competitors? The main competitors of Enzo Biochem include Quipt Home Medical (QIPT), Global Cord Blood (CORBF), EUDA Health (EUDA), P3 Health Partners (PIII), Burning Rock Biotech (BNR), Exagen (XGN), Oncology Institute (TOI), Concord Medical Services (CCM), Psychemedics (PMD), and Marpai (MRAI). These companies are all part of the "healthcare" industry.
Enzo Biochem vs.
Enzo Biochem (NYSE:ENZ) and Quipt Home Medical (NASDAQ:QIPT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.
Quipt Home Medical has a consensus price target of $6.25, suggesting a potential upside of 106.95%. Given Quipt Home Medical's stronger consensus rating and higher probable upside, analysts clearly believe Quipt Home Medical is more favorable than Enzo Biochem.
Quipt Home Medical has higher revenue and earnings than Enzo Biochem.
Quipt Home Medical has a net margin of -2.66% compared to Enzo Biochem's net margin of -75.34%. Quipt Home Medical's return on equity of -6.18% beat Enzo Biochem's return on equity.
Enzo Biochem has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Quipt Home Medical has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500.
Enzo Biochem received 181 more outperform votes than Quipt Home Medical when rated by MarketBeat users. However, 83.78% of users gave Quipt Home Medical an outperform vote while only 54.22% of users gave Enzo Biochem an outperform vote.
36.9% of Enzo Biochem shares are owned by institutional investors. Comparatively, 42.9% of Quipt Home Medical shares are owned by institutional investors. 11.4% of Enzo Biochem shares are owned by company insiders. Comparatively, 4.2% of Quipt Home Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Enzo Biochem had 5 more articles in the media than Quipt Home Medical. MarketBeat recorded 8 mentions for Enzo Biochem and 3 mentions for Quipt Home Medical. Quipt Home Medical's average media sentiment score of 0.46 beat Enzo Biochem's score of 0.20 indicating that Quipt Home Medical is being referred to more favorably in the news media.
Summary
Quipt Home Medical beats Enzo Biochem on 12 of the 17 factors compared between the two stocks.
Get Enzo Biochem News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENZ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enzo Biochem Competitors List
Related Companies and Tools
This page (NYSE:ENZ) was last updated on 1/20/2025 by MarketBeat.com Staff
Free ENZ Stock Alerts